Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib and Pembrolizumab Maintenance in Stage IV Non-Squamous NSCLC
NCT03559049Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2018
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rucaparib in non-small cell lung cancer (NSCLC), sponsored by University of Michigan Rogel Cancer Center. Started Dec 2018; status: terminated.
02
Drugs
rucaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03559049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03559049.